SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...
Ladenburg Thalmann initiated coverage of Artelo Biosciences (NASDAQ:ARTL) with a “buy” rating and price target of $7. The stock closed at $1.63 on Feb. 11. Artelo is developing first-in-class, proprietary therapeutics...
H.C. Wainwright launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and $7 price target. The stock closed at $3.75 on Feb. 10. Plus is focused on developing novel therapies against brain cancer. The...
Maxim Group initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $24 price target. The stock closed at $9.91 on Feb. 9. TRACON is developing a differentiated anti-PD-L1 checkpoint...
Maxim Group more than doubled its price target for Cyclo Therapeutics (NASDAQ:CYTH) to $25 from $12, citing updates from the Phase 1 and Phase 1/2 clinical programs for Trapsol Cyclo (TC) in Neimann-Pick Type C (NPC)...
SVB Leerink launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “outperform” rating and a $34 price target. The stock closed at $14.99 on Feb. 5. Eledon is developing AT-1501, a potentially best-in-class...
Maxim Group raised its price target for Lineage Cell Therapeutics (NYSE American:LCTX) to $5 from $3, citing an agreement with Neurgain Technologies to develop a novel parenchymal delivery injection (PDI) system for...
Maxim Group upgraded BrainStorm Cell Therapeutics (NASDAQ:BCLI) to “buy” from “hold” with a price target of $12, citing a pullback in the stock since the ALS Phase 3 results in the fourth quarter of 2020, opportunities...
H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...
Dawson Jones Securities initiated coverage of Aditxt Therapeutics (NASDAQ:ADTX) with a “buy” rating and $14 price target. The stock closed at $3.34 on Feb. 3. Aditxt has developed a unique antibody test that measures a...
Piper Sandler initiated coverage of Surgalign Holdings (NASDAQ:SRGA) with an “overweight” rating and $4 price target. The stock closed at $1.70 on Feb. 1. The pure-play spine provider has made a big investment in a...
BTIG upgraded Prothena (NASDAQ:PRTA) to “buy” from “neutral” with a new PT of $29, citing meaningful progress of multiple clinical assets and with the potential for more promising opportunities to emerge near term. The...
SVB Leerink initiated coverage of Cullinan Management (NASDAQ:CGEM) with an “outperform” rating and $52 price target. The stock closed at $33.77 on Feb. 1. Cullinan is leveraging a unique “Hub-and-Spoke”...
SVB Leerink launched coverage of Lantheus Holdings (NASDAQ:LNTH) with an “outperform” rating and $24 price target. The stock closed at $16.27 on Jan. 29. Lantheus is a leading player in diagnostic nuclear medicine...
William Blair initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with an “outperform” rating and fair value estimate of $29. The stock closed at $15.44 on Jan. 29. Larimar is developing intracellular-targeted...
Alliance Global Partners launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and price target of $10.75. The stock closed at $3.55 on Jan. 28. “After two disappointing, yet entirely explainable...
Analysts for BTIG, Canaccord Genuity and Alliance Global Partners had mixed reviews of preliminary fourth quarter results for T2 Biosystems (NASDAQ:TTOO),a leader in the rapid detection of sepsis-causing pathogens. Mark...
BTIG raised its price target for OncoCyte (NYSE American:OCX) to $8 from $5, citing a recent direct offering of $25-million with its two largest institutional shareholders, which gives the company “ammunition to execute...
Mackie Research Capital downgraded Cipher Pharmaceuticals (TSX:CPH) to “hold” from “buy” and reduced its price target to $1 (Canadian) from $1.50, citing marketing uncertainty, partially due to a recent unfavorable...
Mackie Research Capital raised its price target for Aleafia Health (TSX:AH) to $1.50 (Canadian) from $1, citing an exclusive agreement with Unifor, Canada’s largest private sector union, to support medical cannabis for...
Ladenburg Thalmann launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with a “buy” rating and $40 price target. The stock closed at $21.78 on Jan. 22. Viridian’s lead asset, VRDN-001, is an anti-IGF-1R monoclonal...
Ladenburg Thalmann initiated coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $8. The stock closed at $2.43 on Jan. 22. The company’s lead product, rhenium nanoliposome (RNL), is a...